Analysts Set Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Target Price at $9.83

by · The Markets Daily

Shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX – Get Free Report) have received an average recommendation of “Moderate Buy” from the eleven ratings firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $9.8333.

BDTX has been the topic of a number of analyst reports. HC Wainwright restated a “buy” rating on shares of Black Diamond Therapeutics in a research report on Friday, May 22nd. Raymond James Financial reissued an “outperform” rating on shares of Black Diamond Therapeutics in a research note on Friday, May 22nd. Jefferies Financial Group upgraded Black Diamond Therapeutics to a “strong-buy” rating in a report on Thursday, April 23rd. Weiss Ratings lowered Black Diamond Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, July 13th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Black Diamond Therapeutics in a research report on Friday, May 22nd.

View Our Latest Analysis on BDTX

Black Diamond Therapeutics Trading Down 1.7%

NASDAQ BDTX opened at $1.73 on Tuesday. The firm has a market cap of $99.13 million, a PE ratio of -2.25 and a beta of 3.25. Black Diamond Therapeutics has a 1-year low of $1.60 and a 1-year high of $4.94. The stock has a 50-day moving average of $1.99 and a 200-day moving average of $2.33.

Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.02. As a group, equities research analysts forecast that Black Diamond Therapeutics will post -0.6 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Black Diamond Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Cerity Partners LLC bought a new position in Black Diamond Therapeutics during the 2nd quarter valued at approximately $26,000. Hudson Bay Capital Management LP bought a new stake in Black Diamond Therapeutics in the second quarter worth $26,000. nVerses Capital LLC purchased a new stake in shares of Black Diamond Therapeutics in the fourth quarter worth $26,000. Stokes Family Office LLC purchased a new stake in shares of Black Diamond Therapeutics in the fourth quarter worth $27,000. Finally, Brookstone Capital Management purchased a new stake in shares of Black Diamond Therapeutics in the first quarter worth $30,000. 95.47% of the stock is owned by hedge funds and other institutional investors.

Black Diamond Therapeutics Company Profile

(Get Free Report)

Black Diamond Therapeutics, Inc is a precision oncology company focused on the discovery and development of small-molecule therapies that selectively target oncogenic proteins bearing tumor-driving mutations. Leveraging its proprietary Genetic Defined Allosteric (GDA) therapeutic platform, the company aims to identify unique allosteric binding sites in mutant proteins and engineer highly selective inhibitors. Headquartered in Cambridge, Massachusetts, Black Diamond applies structure-based drug design and molecular modeling to advance personalized cancer treatments.

The company’s development pipeline includes lead candidate BDTX-189, an allosteric inhibitor of mutant HER2, as well as programs directed at clinically relevant EGFR and KRAS mutations.

Featured Stories